# US 7,608,413 B1 · Kidney disease targets and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,608,413 B1
- Document ID: US7608413B1
- Status: Granted
- Kind: B1
- Application number: 11/878,050
- Filed: 2007-07-20
- Granted: 2009-10-27
- Earliest claimed: 2005-03-25
- Assignees: Celera Corporation
- Inventors: Elizabeth Joseloff; Steve Ruben; Tao He; Yeoun Jim Kim
- Web page: https://patentgrep.com/patent/US7608413B1

## CPC

- C07K 14/47: from mammals
- A61P 13/12: of the kidneys
- A61P 35/00: Antineoplastic agents
- C07K 14/435: from animals; from humans
- C07K 16/18: against material from animals or humans
- C07K 16/3038: {Kidney, bladder}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 33/57525: of the liver or pancreas
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 2310/14: interfering nucleic acids [NA]
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2500/10: involving cells
- Y10T 436/143333: Saccharide [e.g., DNA, etc.]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.

## Claims

### Claim 1

A method of diagnosing kidney cancer in an individual, the method comprising detecting an elevated level of ABC 1 protein in a sample from the individual as compared to a control ABC 1 protein level of an individual who does not have kidney cancer, wherein the elevated level of ABC1 protein indicates that said individual has kidney cancer, wherein the amino acid sequence of the ABC1 protein comprises a sequence selected from the group consisting of SEQ ID NOS: 275-276.

### Claim 2 (depends on 1)

The method of claim 1, wherein the amino acid sequence of the ABC1 protein consists of a sequence selected from the group consisting of SEQ ID NOS: 275-276.

### Claim 3 (depends on 1)

The method of claim 1, wherein the higher level of ABC 1 protein is detected by contacting the sample with an isolated antibody that selectively binds to the ABC 1 protein and detecting binding of the antibody to the ABC 1 protein.

### Claim 4 (depends on 3)

The method of claim 3, wherein the antibody is coupled to a detectable substance.